- Arcinova, a UK-based CRDMO and Quotient Sciences company, appoints Dr Christian Dowdeswell as Managing Director following Paul Ryan’s retirement.
- The Alnwick facility recently received £6.3 million investment to expand its 1,500 m² GMP manufacturing suite, enhancing aseptic capabilities and supporting integrated drug substance and early drug product services.
Arcinova, a UK Contract Research, Development and Manufacturing Organisation (CRDMO) and part of Quotient Sciences, has appointed Dr Christian Dowdeswell as its new Managing Director. He succeeds co-founder Paul Ryan, who retired recently. Dr Dowdeswell joins the company during a period of growth, coinciding with a refreshed brand identity and a strategic focus on integrated drug substance and early drug product services.
Located in Alnwick, Arcinova has benefited from £6.3 million in investment over the past three to four years to establish a 1,500 square-metre GMP manufacturing suite. The facility now features 14 GMP manufacturing streams, capable of producing drug substance from early-stage development to multi-kilo scale batches.
Recent upgrades include enhanced aseptic manufacturing capabilities that meet the latest Annex 1 compliance standards. These improvements strengthen Arcinova’s ability to support complex and high-quality contract manufacturing projects for global biotech and pharmaceutical clients.
Dr Dowdeswell brings over 25 years of experience, having held senior roles at Lonza and Siegfried AG, as well as consulting positions at Nanoform and Pangaea Life Sciences. On his appointment, he said: “Arcinova has an outstanding reputation for innovation, agility, and scientific excellence—qualities our clients depend on.”
Thierry Van Nieuwenhove, CEO of Quotient Sciences, welcomed the new Managing Director, highlighting his expertise in the global CDMO market as a key asset for Arcinova’s continued growth and client service excellence.
